PubRank

W Martin Kast

Author PubWeight™ 92.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002 4.04
2 Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2007 3.16
3 Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002 2.65
4 Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009 2.59
5 Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 2005 1.44
6 Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008 1.41
7 The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 2012 1.38
8 The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J Immunol 2002 1.30
9 Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 2003 1.27
10 Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007 1.27
11 Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007 1.26
12 The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol 2013 1.20
13 Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009 1.19
14 In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007 1.16
15 Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 2008 1.13
16 Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006 1.12
17 Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002 1.12
18 Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004 1.12
19 Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate 2011 1.11
20 AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol 2008 1.11
21 Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003 1.11
22 Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 2011 1.06
23 Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep 2013 1.06
24 Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 2008 1.06
25 A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol 2009 1.05
26 Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol 2005 1.03
27 Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 2007 1.02
28 The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol 2011 1.01
29 HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol 2003 0.99
30 Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 2009 0.98
31 Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem 2004 0.96
32 Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 2003 0.95
33 The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res 2002 0.95
34 CD4+ T cell matters in tumor immunity. Int Rev Immunol 2003 0.93
35 Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol 2011 0.93
36 A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 2008 0.92
37 T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 2005 0.91
38 Ins and outs of clinical trials with peptide-based vaccines. Front Biosci 2002 0.91
39 Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002 0.91
40 Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002 0.91
41 Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res 2010 0.90
42 Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2009 0.90
43 Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One 2010 0.89
44 Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 2006 0.89
45 Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene 2004 0.89
46 Emerging strategies in tumor vaccines. Curr Opin Oncol 2002 0.89
47 Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res 2009 0.88
48 HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci 2003 0.88
49 Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res 2004 0.87
50 Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol 2014 0.87
51 Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Transl Med 2007 0.87
52 Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine 2009 0.86
53 Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004 0.86
54 Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother 2007 0.85
55 Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007 0.85
56 Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett 2011 0.85
57 Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax. J Transl Med 2007 0.85
58 Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol 2012 0.84
59 Is sperm protein 17 a useful target for tumor immunotherapy? Blood 2003 0.84
60 Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother 2011 0.84
61 Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med 2006 0.84
62 Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med 2009 0.84
63 Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines 2008 0.84
64 Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol Oncol 2009 0.83
65 Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother 2008 0.83
66 Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol 2005 0.82
67 The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 2007 0.82
68 Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003 0.82
69 Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol 2007 0.81
70 Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010 0.81
71 rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol 2008 0.80
72 Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun 2008 0.79
73 Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest 2004 0.79
74 Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol 2005 0.79
75 Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro. Methods Mol Biol 2015 0.79
76 Recent progress in tumour vaccine development. Expert Opin Investig Drugs 2003 0.79
77 Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine 2005 0.79
78 Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother 2008 0.79
79 Functional analysis of HPV-like particle-activated Langerhans cells in vitro. Methods Mol Biol 2015 0.78
80 Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol 2012 0.77
81 Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting. Mol Interv 2010 0.77
82 A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods 2007 0.77
83 Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol 2011 0.76
84 Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 2002 0.76
85 Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. Vaccine 2003 0.76
86 Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate 2014 0.76
87 A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med 2012 0.76
88 Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med 2008 0.75
89 Cure of glioma: a space not yet occupied for the lesion. Cancer Invest 2004 0.75
90 Advances in prophylactic cancer vaccine research. Expert Rev Anticancer Ther 2003 0.75
91 Synopsis of the 4th Walker's Cay Meeting on Cancer Vaccines, 7-10 March 2002. Cancer Immunol Immunother 2002 0.75
92 Advances in immunotherapy for prostate cancer. Adv Cancer Res 2003 0.75
93 Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay. Cancer Immunol Immunother 2003 0.75
94 In this issue: targeting Human Papilloma Virus-associated disease, from cervical to head and neck carcinoma…and more. Int Rev Immunol 2012 0.75